margins were negative. Imaging revealed no evidence of metastasis. She received adjuvant chemotherapy with 4 cycles of doxorubicin and cyclophosphamide, followed by 4 cycles of paclitaxel with concurrent trastuzumab. She underwent photon irradiation using
Search Results
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli
Treatment of Cancer-Associated Retinopathy With Rituximab
Irene Dy, Rangaswamy Chintapatla, Isabel Preeshagul, and Daniel Becker
initiated for worsening vision 13 months after diagnosis. She progressed through third-line chemotherapy and started paclitaxel 16 months after diagnosis. At that time she was able to drive during the daytime and ski. She died from disease progression 18
Small Cell Lung Cancer
Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo Jr, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O’Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams Jr, Kristina Gregory, and Miranda Hughes
, the addition of paclitaxel to either cisplatin or carboplatin plus etoposide yielded promising results in phase II trials but did not improve survival, and was associated with unacceptable toxicity in a subsequent phase III study. 72 The use of
Real Personalized Medicine
James O. Armitage, William C. Wood, and Dan L. Longo
-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study . Blood 2007 ; 109 : 1408 – 1413 . 13. Mok TS Wu YL Thongprasert S . Fefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957
NCCN Roundtable:Value-Based Decision-Making at the Bedside
Peter B. Bach, Stephen B. Edge, Linda House, Jennifer Malin, James L. Mohler, and Clifford Goodman
practices derive the bulk of their revenue from drug margins. For example, in the case of non-small cell lung cancer, regimens can range from $450 for 4 cycles of carboplatin/paclitaxel to $65,000 for 4 cycles of 3 other agents. Depending on which regimen is
Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression
Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff, and Hannah M. Linden
, spine), treatment was switched to weekly paclitaxel and disease control was seen for 1 year, but then the tumor again progressed in bone and soft tissue, with worsening pain, increasing and diffuse bone and bone marrow involvement shown on FDG
Treatment of Metastatic Breast Cancer
William J. Gradishar
that triple-drug regimen significantly prolonged progression-free and overall survivals. Paclitaxel could be used instead of docetaxel in this triplet, and this is noted in the NCCN Guidelines for Breast Cancer. Trastuzumab in combination with eribulin
Combined Modality Therapy of Localized Gastric and Esophageal Cancers
Prajnan Das, Norio Fukami, and Jaffer A. Ajani
patients with potentially resectable gastric carcinoma . J Clin Oncol 2004 ; 22 : 2774 – 2780 . 41. Ajani JA Mansfield PF Crane CH . Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not
Novel Targets for Therapeutic Agents in Small Cell Lung Cancer
Patrick C. Ma and Ravi Salgia
Oncol Clin North Am 1995 ; 9 : 451 – 473 . 55 Rudin CM Otterson GA Mauer AM . A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer . Ann Oncol 2002 ; 13 : 539
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Featured Updates to the NCCN Guidelines
Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, and Lisa A. Gurski
bladder cancer who previously received chemotherapy and subsequently experienced disease progression or metastasis. 50 An open-label, randomized, phase III trial compared pembrolizumab versus chemotherapy (paclitaxel, docetaxel, or vinflunine) in 542